ZBD's subsidiary Fuma Suan Bisoprolol Tablets has obtained a drug registration certificate
I'm LongbridgeAI, I can summarize articles.ZBD's wholly-owned subsidiary Harbin Zhenbao Pharmaceutical Co., Ltd. recently obtained the "Drug Registration Certificate" for Bisoprolol Fumarate Tablets issued by the National Medical Products Administration. This medication is used to treat hypertension, coronary heart disease, and chronic stable heart failure. This certificate indicates that the drug meets national drug review standards and will be produced and sold in the domestic market, enriching the company's product line and enhancing market competitiveness, but it will not have a significant impact on the company's current operating performance
According to the Zhontong Finance APP, ZBD (603567.SH) announced that its wholly-owned subsidiary Harbin Zhenbao Pharmaceutical Co., Ltd. has received the "Drug Registration Certificate" for Bisoprolol Fumarate Tablets issued by the National Medical Products Administration. Bisoprolol Fumarate Tablets are used to treat hypertension and coronary heart disease (angina), accompanied by chronic stable heart failure with reduced left ventricular systolic function (ejection fraction ≤ 35%).
The acquisition of the "Drug Registration Certificate" for Bisoprolol Fumarate Tablets indicates that this product meets the national drug review technical standards and can be produced and sold in the domestic market. This will further enrich the company's product line, help expand the company's business scope, and enhance the market competitiveness of the company's products. The above matters will not have a significant impact on the company's current operating performance